Adaptive Biotechnologies Corp Stock Buy Hold or Sell Recommendation
| ADPT Stock | USD 7.28 0.11 1.53% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Adaptive Biotechnologies Corp is 'Buy'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Adaptive Biotechnologies Corp given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Adaptive Biotechnologies Corp, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Adaptive Biotechnologies Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Adaptive and provide practical buy, sell, or hold advice based on investors' constraints. Adaptive Biotechnologies Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Adaptive |
Execute Adaptive Biotechnologies Buy or Sell Advice
The Adaptive recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Adaptive Biotechnologies Corp. Macroaxis does not own or have any residual interests in Adaptive Biotechnologies Corp or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Adaptive Biotechnologies' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Buy
Market Performance | Insignificant | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Adaptive Biotechnologies Trading Alerts and Improvement Suggestions
| Adaptive Biotechnologies had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 178.96 M. Net Loss for the year was (159.59 M) with profit before overhead, payroll, taxes, and interest of 89.8 M. | |
| Adaptive Biotechnologies Corp currently holds about 383.74 M in cash with (95.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69. | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 53000 shares by Hershberg Robert of Adaptive Biotechnologies at 7.59 subject to Rule 16b-3 |
Adaptive Biotechnologies Returns Distribution Density
The distribution of Adaptive Biotechnologies' historical returns is an attempt to chart the uncertainty of Adaptive Biotechnologies' future price movements. The chart of the probability distribution of Adaptive Biotechnologies daily returns describes the distribution of returns around its average expected value. We use Adaptive Biotechnologies Corp price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Adaptive Biotechnologies returns is essential to provide solid investment advice for Adaptive Biotechnologies.
| Mean Return | 0.35 | Value At Risk | -5.91 | Potential Upside | 12.29 | Standard Deviation | 5.21 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Adaptive Biotechnologies historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Adaptive Stock Institutional Investors
The Adaptive Biotechnologies' institutional investors refer to entities that pool money to purchase Adaptive Biotechnologies' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | State Street Corp | 2024-12-31 | 2.7 M | Geode Capital Management, Llc | 2024-12-31 | 2.7 M | Ing Investment Management Llc | 2024-12-31 | 2.4 M | Goldman Sachs Group Inc | 2024-12-31 | 2.2 M | Blue Water Life Science Advisors, Llc | 2024-12-31 | 2.1 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.6 M | Pier Capital, Llc | 2024-12-31 | 1.3 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.2 M | Northern Trust Corp | 2024-12-31 | 1.1 M | Viking Global Investors Lp | 2024-12-31 | 30 M | Rubric Capital Management Lp | 2024-12-31 | 14.6 M |
Adaptive Biotechnologies Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (5.0M) | (5.2M) | 817K | 1.4M | 1.9M | 2.0M | |
| Investments | (98.2M) | 243.0M | 2.9M | 28.9M | 77.8M | 81.7M | |
| Change In Cash | 26.9M | 15.6M | (48.8M) | (24.4M) | (17.2M) | (16.3M) | |
| Free Cash Flow | (168.5M) | (254.5M) | (200.3M) | (167.0M) | (98.9M) | (103.8M) | |
| Depreciation | 8.5M | 14.0M | 20.9M | 22.2M | 19.3M | 14.4M | |
| Other Non Cash Items | 3.3M | 7.0M | 11.6M | 30.0M | 9.0M | 8.4M | |
| Capital Expenditures | 18.8M | 61.7M | 16.3M | 10.7M | 3.7M | 3.5M | |
| Net Income | (146.2M) | (207.3M) | (200.4M) | (225.3M) | (159.6M) | (167.6M) | |
| End Period Cash Flow | 125.6M | 141.2M | 92.4M | 68.0M | 50.8M | 71.7M | |
| Change To Netincome | 11.3M | 24.8M | 43.2M | 56.4M | 64.9M | 68.2M |
Adaptive Biotechnologies Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Adaptive Biotechnologies or Life Sciences Tools & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Adaptive Biotechnologies' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Adaptive stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.59 | |
β | Beta against Dow Jones | 2.27 | |
σ | Overall volatility | 5.24 | |
Ir | Information ratio | 0.09 |
Adaptive Biotechnologies Volatility Alert
Adaptive Biotechnologies Corp shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Adaptive Biotechnologies' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Adaptive Biotechnologies' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Adaptive Biotechnologies Fundamentals Vs Peers
Comparing Adaptive Biotechnologies' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Adaptive Biotechnologies' direct or indirect competition across all of the common fundamentals between Adaptive Biotechnologies and the related equities. This way, we can detect undervalued stocks with similar characteristics as Adaptive Biotechnologies or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Adaptive Biotechnologies' fundamental indicators could also be used in its relative valuation, which is a method of valuing Adaptive Biotechnologies by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Adaptive Biotechnologies to competition |
| Fundamentals | Adaptive Biotechnologies | Peer Average |
| Return On Equity | -0.62 | -0.31 |
| Return On Asset | -0.16 | -0.14 |
| Profit Margin | (0.89) % | (1.27) % |
| Operating Margin | (0.71) % | (5.51) % |
| Current Valuation | 932.43 M | 16.62 B |
| Shares Outstanding | 148.58 M | 571.82 M |
| Shares Owned By Insiders | 2.30 % | 10.09 % |
| Shares Owned By Institutions | 94.00 % | 39.21 % |
| Number Of Shares Shorted | 8.78 M | 4.71 M |
| Price To Earning | 0.25 X | 28.72 X |
| Price To Book | 5.26 X | 9.51 X |
| Price To Sales | 6.04 X | 11.42 X |
| Revenue | 178.96 M | 9.43 B |
| Gross Profit | 89.8 M | 27.38 B |
| EBITDA | (128.76 M) | 3.9 B |
| Net Income | (159.59 M) | 570.98 M |
| Cash And Equivalents | 383.74 M | 2.7 B |
| Cash Per Share | 2.69 X | 5.01 X |
| Total Debt | 89.39 M | 5.32 B |
| Debt To Equity | 0.21 % | 48.70 % |
| Current Ratio | 3.93 X | 2.16 X |
| Book Value Per Share | 1.37 X | 1.93 K |
| Cash Flow From Operations | (95.21 M) | 971.22 M |
| Short Ratio | 5.84 X | 4.00 X |
| Earnings Per Share | (1.08) X | 3.12 X |
| Target Price | 9.57 | |
| Number Of Employees | 619 | 18.84 K |
| Beta | 1.53 | -0.15 |
| Market Capitalization | 1.08 B | 19.03 B |
| Total Asset | 539.38 M | 29.47 B |
| Retained Earnings | (1.3 B) | 9.33 B |
| Working Capital | 185.7 M | 1.48 B |
| Current Asset | 118.69 M | 9.34 B |
Note: Disposition of 53000 shares by Hershberg Robert of Adaptive Biotechnologies at 7.59 subject to Rule 16b-3 [view details]
Adaptive Biotechnologies Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Adaptive . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Adaptive Biotechnologies Buy or Sell Advice
When is the right time to buy or sell Adaptive Biotechnologies Corp? Buying financial instruments such as Adaptive Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Adaptive Biotechnologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Diversified Assets Thematic Idea Now
Diversified Assets
Pablicly traded close-end funds and other entities backed by different types of diversified investments. The Diversified Assets theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Diversified Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.